Pulmonary Vascular Remodelling: Pathogenesis, Clinical Implications, and Therapeutic Approaches

Abstract

Pulmonary vascular remodelling is a central pathophysiological process underpinning various forms of pulmonary hypertension, leading to significant morbidity and mortality worldwide. Characterised by structural and functional alterations of the pulmonary vasculature, this phenomenon involves endothelial dysfunction, smooth muscle proliferation, inflammatory infiltration, and extracellular matrix changes. Recent advances in molecular biology, imaging, and therapeutics have provided deeper insights into the mechanisms driving remodelling and have paved the way for emerging targeted interventions. This comprehensive review synthesises current evidence on pulmonary vascular remodelling, including epidemiological trends, underlying mechanisms, clinical manifestations, diagnostic strategies, management options, and guideline-based recommendations, with a focus on practical implications for clinicians.

Introduction

Pulmonary vascular remodelling refers to a series of maladaptive structural and cellular changes in the pulmonary arteries, which contribute to elevated pulmonary vascular resistance and pulmonary hypertension (PH). These changes are not only a hallmark of idiopathic pulmonary arterial hypertension (PAH) but are also observed in secondary PH associated with left heart disease, chronic lung diseases, and thromboembolic conditions. As understanding of the molecular underpinnings of remodelling has advanced, so too has recognition of its importance in determining clinical outcomes, therapeutic response, and prognosis. This review aims to elucidate key aspects of pulmonary vascular remodelling and their relevance in everyday clinical practice.

Epidemiology / Disease Burden

Pulmonary hypertension, driven in part by vascular remodelling, affects approximately 1% of the global population, with a markedly higher prevalence in high-risk groups such as patients with connective tissue diseases, congenital heart disease, chronic obstructive pulmonary disease (COPD), and those exposed to certain drugs and toxins. Idiopathic PAH remains rare, with an estimated incidence of 2-7 cases per million annually, but secondary forms are increasingly recognised due to the ageing population and improved diagnostic capabilities. The burden of disease is substantial, with five-year survival rates for PAH ranging from 30–65% despite advances in therapy, underscoring the clinical significance of remodelling as a therapeutic target.

Pathophysiology

The pathogenesis of pulmonary vascular remodelling is multifactorial, involving genetic predisposition, environmental insults, and dysregulation of signalling pathways. Key mechanisms include endothelial dysfunction with reduced nitric oxide and prostacyclin production, increased endothelin-1 expression, and upregulation of growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-β). These changes promote proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), adventitial fibroblast activation, and perivascular inflammation. The resultant intimal and medial thickening, adventitial fibrosis, and in situ thrombosis reduce vascular compliance and lumen diameter, precipitating increased pulmonary pressures. Emerging data highlight the role of metabolic dysregulation, mitochondrial dysfunction, and microRNA alterations in sustaining the remodelling process.

Risk Factors

Numerous risk factors contribute to the development and progression of pulmonary vascular remodelling. Genetic mutations, particularly in the bone morphogenetic protein receptor type 2 (BMPR2) gene, account for a significant proportion of heritable PAH cases. Other risk factors include chronic hypoxia (as seen in interstitial lung disease and COPD), left-sided heart dysfunction, systemic autoimmune diseases (e.g., scleroderma), chronic thromboembolic disease, HIV infection, portal hypertension, and exposure to anorexigens or chemotherapy agents. Age, female sex, and family history further modulate risk profiles and disease trajectory.

Clinical Features

Patients with pulmonary vascular remodelling often present with nonspecific symptoms such as progressive exertional dyspnoea, fatigue, chest discomfort, palpitations, and syncope. As remodelling advances and pulmonary pressures rise, right ventricular dysfunction ensues, manifesting as peripheral oedema, jugular venous distension, and hepatomegaly. Physical examination may reveal a loud P2, right ventricular heave, and tricuspid regurgitation murmur. The insidious onset and overlap with other cardiopulmonary diseases often delay diagnosis, highlighting the need for heightened clinical suspicion in at-risk populations.

Diagnosis

The diagnostic approach to pulmonary vascular remodelling necessitates a combination of clinical evaluation, imaging, and haemodynamic assessment. Transthoracic echocardiography serves as a non-invasive screening tool, providing estimates of pulmonary artery pressures and right ventricular function. Definitive diagnosis is established via right heart catheterisation, which quantifies pulmonary haemodynamics and differentiates pre- from post-capillary PH. Cardiac MRI, CT pulmonary angiography, and ventilation-perfusion scans may assist in evaluating vascular morphology and excluding alternative causes such as chronic thromboembolic PH. Biomarkers, including NT-proBNP and troponins, offer prognostic information but lack specificity for remodelling per se. Histopathological examination of pulmonary vessels, although rarely performed, remains the gold standard for characterising the extent and nature of remodelling.

Treatment & Management

Management of pulmonary vascular remodelling is tailored to the underlying aetiology, disease severity, and individual patient characteristics. General measures include optimisation of comorbid conditions, supplemental oxygen in hypoxic patients, diuretics for right heart failure, and anticoagulation in select cases. Targeted pharmacotherapy for PAH has revolutionised outcomes, with agents such as endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE5i), soluble guanylate cyclase stimulators, and prostacyclin analogues demonstrating efficacy in attenuating remodelling and improving functional capacity. Combination therapy is increasingly advocated based on evidence from recent trials. In advanced cases refractory to medical therapy, lung transplantation remains the definitive option, though access and eligibility pose significant challenges.

Recent Advances / Emerging Therapies

Recent research has focused on elucidating novel molecular targets and developing innovative therapies to halt or reverse pulmonary vascular remodelling. Agents targeting the TGF-β pathway, tyrosine kinase inhibitors (e.g., imatinib), and anti-inflammatory strategies are under active investigation. Cell-based therapies, including endothelial progenitor cell transplantation and gene therapy targeting BMPR2 and related pathways, hold promise in early-phase studies. Advances in non-invasive imaging modalities, such as positron emission tomography (PET) using novel tracers, are enhancing our ability to monitor vascular remodelling in vivo. Ongoing clinical trials and precision medicine approaches are expected to refine patient selection and therapeutic algorithms in the coming years.

Guideline Recommendations

Current guidelines from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) emphasise early recognition, accurate phenotyping, and risk stratification in patients with suspected pulmonary hypertension. Multidisciplinary management in expert centres is recommended, with periodic re-assessment to guide escalation of therapy. Upfront combination therapy is endorsed for high-risk patients, while monotherapy may suffice in lower-risk cases. The importance of addressing modifiable risk factors, ensuring adherence to evidence-based pharmacotherapy, and timely referral for advanced therapies is consistently highlighted. Ongoing updates integrate emerging evidence and novel agents as they become available.

Conclusion

Pulmonary vascular remodelling represents a complex, multifaceted process with profound clinical implications. Advances in understanding its molecular basis have translated into improved diagnostic and therapeutic strategies, yet significant unmet needs remain. Continued research into the cellular and genetic drivers of remodelling, coupled with the development of targeted therapies and implementation of guideline-based care, is essential to improving outcomes for patients with pulmonary hypertension. Clinicians must maintain a high index of suspicion, employ a systematic diagnostic approach, and individualise management to optimise care in this challenging and evolving field.